Cancer risks from diabetes therapies: Evaluating the evidence

Pharmacology and Therapeutics

Volumn 144, Issue 1, 2014, Pages 71-81

  Li, Chen ^a   Kong, Deling ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Anti diabetics; Cancer; Cannabinoid; Diabetes; Insulin; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; ENDOCANNABINOID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN RECEPTOR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOMEDIN;

ANTIDIABETIC ACTIVITY; CANCER RISK; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; DIABETES MELLITUS; DIABETIC PATIENT; EVALUATION STUDY; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEALTH CARE FINANCING; HUMAN; HYPERGLYCEMIA; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN; ANIMAL; COMPLICATION; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; DIABETES MELLITUS; DRUG DESIGN; ENDOCANNABINOIDS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MOLECULAR TARGETED THERAPY; NEOPLASMS; OBESITY;

EID: 84906937118     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.05.006     Document Type: Review

References (96)

1. C. Addy, P. Rothenberg, S. Li, A. Majumdar, N. Agrawal, and H. Li et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers J Clin Pharmacol 48 2008 734 744
2. T. Aguado, K. Monory, J. Palazuelos, N. Stella, B. Cravatt, and B. Lutz et al. The endocannabinoid system drives neural progenitor proliferation FASEB J 19 2005 1704 1706
3. A. Aljada, and S.A. Mousa Metformin and neoplasia: implications and indications Pharmacol Ther 133 2012 108 115
4. E.A. Atchison, G. Gridley, J.D. Carreon, M.F. Leitzmann, and K.A. McGlynn Risk of cancer in a large cohort of U.S. veterans with diabetes Int J Cancer 128 2011 635 643
5. Y. Barak, M.C. Nelson, E.S. Ong, Y.Z. Jones, P. Ruiz-Lozano, and K.R. Chien et al. PPAR gamma is required for placental, cardiac, and adipose tissue development Mol Cell 4 1999 585 595
6. R. Baserga, F. Peruzzi, and K. Reiss The IGF-1 receptor in cancer biology Int J Cancer 107 2003 873 877
7. S.P. Berasi, C. Huard, D. Li, H.H. Shih, Y. Sun, and W. Zhong et al. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase J Biol Chem 281 2006 27167 27177
8. M. Bluher Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes 19 2012 341 346
9. V. Brower Illuminating the diabetes-cancer link J Natl Cancer Inst 104 2012 1048 1050
10. W.H. Brown, M.P. Gillum, H.Y. Lee, J.P. Camporez, X.M. Zhang, and J.K. Jeong et al. Fatty acid amide hydrolase ablation promotes ectopic lipid storage and insulin resistance due to centrally mediated hypothyroidism Proc Natl Acad Sci USA 109 2012 14966 14971
11. J.C. Bruning, J. Winnay, B. Cheatham, and C.R. Kahn Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells Mol Cell Biol 17 1997 1513 1521
12. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, and M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638
13. C. Canto, and J. Auwerx Calorie restriction: is AMPK a key sensor and effector? Physiology (Bethesda) 26 2011 214 224
14. B. Cariou, B. Charbonnel, and B. Staels Thiazolidinediones and PPARgamma agonists: time for a reassessment Trends Endocrinol Metab 23 2012 205 215
15. J.H. Choi, A.S. Banks, J.L. Estall, S. Kajimura, P. Bostrom, and D. Laznik et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5 Nature 466 2010 451 456
16. S.S. Chung, M. Kim, J.S. Lee, B.Y. Ahn, H.S. Jung, and H.M. Lee et al. Mechanism for antioxidative effects of thiazolidinediones in pancreatic beta-cells Am J Physiol Endocrinol Metab 301 2011 E912 E921
17. G. Cohen, Y. Riahi, O. Shamni, M. Guichardant, C. Chatgilialoglu, and C. Ferreri et al. Role of lipid peroxidation and PPAR-delta in amplifying glucose-stimulated insulin secretion Diabetes 60 2011 2830 2842
18. K.D. Copps, and M.F. White Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2 Diabetologia 55 2012 2565 2582
19. C.J. Currie, C.D. Poole, and E.A. Gale The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 52 2009 1766 1777
20. N. Defer, J. Wan, R. Souktani, B. Escoubet, M. Perier, and P. Caramelle et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy FASEB J 23 2009 2120 2130
21. R.A. DeFronzo, D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, and T.A. Buchanan et al. Pioglitazone for diabetes prevention in impaired glucose tolerance N Engl J Med 364 2011 1104 1115
22. J. Downward Cell biology: metabolism meets death Nature 424 2003 896 897
23. P.A. Dutchak, T. Katafuchi, A.L. Bookout, J.H. Choi, R.T. Yu, and D.J. Mangelsdorf et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones Cell 148 2012 556 567
24. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, and A.D. Morris Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
25. M. Foretz, N. Ancellin, F. Andreelli, Y. Saintillan, P. Grondin, and A. Kahn et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver Diabetes 54 2005 1331 1339
26. L.G. Fryer, E. Hajduch, F. Rencurel, I.P. Salt, H.S. Hundal, and D.G. Hardie et al. Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase Diabetes 49 2000 1978 1985
27. S. Galic, J.S. Oakhill, and G.R. Steinberg Adipose tissue as an endocrine organ Mol Cell Endocrinol 316 2010 129 139
28. D. Galuska, J. Zierath, A. Thorne, T. Sonnenfeld, and H. Wallberg-Henriksson Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle Diabete Metab 17 1991 159 163
29. M. Gary-Bobo, G. Elachouri, B. Scatton, G. Le Fur, F. Oury-Donat, and M. Bensaid The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes Mol Pharmacol 69 2006 471 478
30. H.C. Gerstein, S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, and N. Dinccag et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105
31. M.B. Goncalves, P. Suetterlin, P. Yip, F. Molina-Holgado, D.J. Walker, and M.J. Oudin et al. A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner Mol Cell Neurosci 38 2008 526 536
32. D.M. Gwinn, J.M. Asara, and R.J. Shaw Raptor is phosphorylated by cdc2 during mitosis PLoS One 5 2010 e9197
33. D.G. Hardie AMPK: a target for drugs and natural products with effects on both diabetes and cancer Diabetes 62 2013 2164 2172
34. D.G. Hardie, F.A. Ross, and S.A. Hawley AMPK: a nutrient and energy sensor that maintains energy homeostasis Nat Rev Mol Cell Biol 13 2012 251 262
35. B.D. Hegarty, N. Turner, G.J. Cooney, and E.W. Kraegen Insulin resistance and fuel homeostasis: the role of AMP-activated protein kinase Acta Physiol (Oxf) 196 2009 129 145
36. K. Hemminki, X. Li, J. Sundquist, and K. Sundquist Risk of cancer following hospitalization for type 2 diabetes Oncologist 15 2010 548 555
37. C.M. Henstridge Off-target cannabinoid effects mediated by GPR55 Pharmacology 89 2012 179 187
38. E. Heyman, F.X. Gamelin, J. Aucouturier, and V. Di Marzo The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity Obes Rev 13 2012 1110 1124
39. P. Imfeld, M. Bodmer, S.S. Jick, and C.R. Meier Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study J Am Geriatr Soc 60 2012 916 921
40. C.B. Juhl, M. Hollingdal, N. Porksen, A. Prange, F. Lonnqvist, and O. Schmitz Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility J Clin Endocrinol Metab 88 2003 3794 3800
41. W. Keung, J.R. Ussher, J.S. Jaswal, M. Raubenheimer, V.H. Lam, and C.S. Wagg et al. Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice Diabetes 62 2013 711 720
42. T.J. Key, E.A. Spencer, and G.K. Reeves Symposium 1: overnutrition: consequences and solutions. Obesity and cancer risk Proc Nutr Soc 69 2010 86 90
43. W. Kim, M.E. Doyle, Z. Liu, Q. Lao, Y.K. Shin, and O.D. Carlson et al. Cannabinoids inhibit insulin receptor signaling in pancreatic beta-cells Diabetes 60 2011 1198 1209
44. G.W. Landman, L.J. Ubink-Veltmaat, N. Kleefstra, B.J. Kollen, and H.J. Bilo Increased cancer mortality in type 2 diabetes (ZODIAC-3) Anticancer Res 28 2008 1373 1375
45. G.W. Landman, K.J. Van Hateren, N. Kleefstra, and H.J. Bilo The relationship between obesity and cancer mortality in type 2 diabetes: a ten-year follow-up study (ZODIAC-21) Anticancer Res 30 2010 681 682
46. C. Li, P.M. Jones, and S.J. Persaud Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas Pharmacol Ther 129 2011 307 320
47. C. Lipina, C. Stretton, S. Hastings, J.S. Hundal, K. Mackie, and A.J. Irving et al. Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells Diabetes 59 2010 375 385
48. P.A. Lochhead, I.P. Salt, K.S. Walker, D.G. Hardie, and C. Sutherland 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase Diabetes 49 2000 896 903
49. Y.C. Long, Z. Cheng, K.D. Copps, and M.F. White Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways Mol Cell Biol 31 2011 430 441
50. J. Ma, H. Li, E. Giovannucci, L. Mucci, W. Qiu, and P.L. Nguyen et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis Lancet Oncol 9 2008 1039 1047
51. D. Margel, D. Urbach, L.L. Lipscombe, C.M. Bell, G. Kulkarni, and P.C. Austin et al. Association between metformin use and risk of prostate cancer and its grade J Natl Cancer Inst 105 2013 1123 1131
52. I. Matias, B. Gatta-Cherifi, A. Tabarin, S. Clark, T. Leste-Lasserre, and G. Marsicano et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity PLoS One 7 2012 e42399
53. I. Matias, M.P. Gonthier, P. Orlando, V. Martiadis, L. De Petrocellis, and C. Cervino et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia J Clin Endocrinol Metab 91 2006 3171 3180
54. D.E. Moller, and J.P. Berger Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation Int J Obes Relat Metab Disord 27 Suppl. 3 2003 S17 S21
55. H. Mori, K. Inoki, D. Opland, H. Munzberg, E.C. Villanueva, and M. Faouzi et al. Critical roles for the TSC-mTOR pathway in beta-cell function Am J Physiol Endocrinol Metab 297 2009 E1013 E1022
56. S. Murikinati, E. Juttler, T. Keinert, D.A. Ridder, S. Muhammad, and Z. Waibler et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment FASEB J 24 2010 788 798
57. R. Murumalla, K. Bencharif, L. Gence, A. Bhattacharya, F. Tallet, and M.P. Gonthier et al. Effect of the cannabinoid receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation J Inflamm (Lond) 8 2011 33
58. N. Musi, M.F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, and O. Rooyackers et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes Diabetes 51 2002 2074 2081
59. D.K. Nomura, J.Z. Long, S. Niessen, H.S. Hoover, S.W. Ng, and B.F. Cravatt Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis Cell 140 2010 49 61
60. P. Pacher, S. Batkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol Rev 58 2006 389 462
61. C. Pagano, M. Rossato, and R. Vettor Endocannabinoids, adipose tissue and lipid metabolism J Neuroendocrinol 20 Suppl. 1 2008 124 129
62. E. Perez-Gomez, C. Andradas, J.M. Flores, M. Quintanilla, J.M. Paramio, and M. Guzman et al. The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas Oncogene 32 2013 2534 2542
63. P.J. Piatkiewicz, A. Czech, T. Milek, M. Bernat-Karpinska, and A. Gorski Insulin resistance as a link between type 2 diabetes mellitus and colon cancer Diabetologia 55 Suppl. 1 2012 703 (Abstract)
64. M. Pollak Potential applications for biguanides in oncology J Clin Invest 123 2013 3693 3700
65. C. Quarta, R. Mazza, S. Obici, R. Pasquali, and U. Pagotto Energy balance regulation by endocannabinoids at central and peripheral levels Trends Mol Med 17 2011 518 526
66. A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, and M. Zwahlen Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 371 2008 569 578
67. P. Rivera, M.J. Luque-Rojas, A. Pastor, E. Blanco, F.J. Pavon, and A. Serrano et al. Diet-dependent modulation of hippocampal expression of endocannabinoid signaling-related proteins in cannabinoid antagonist-treated obese rats Eur J Neurosci 37 2013 105 117
68. M.E. Roder, D. Porte Jr.; R.S. Schwartz, and S.E. Kahn Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus J Clin Endocrinol Metab 83 1998 604 608
69. S.Y. Romero-Zerbo, M.S. Garcia-Gutierrez, J. Suarez, P. Rivera, I. Ruz-Maldonado, and M. Vida et al. Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice J Neuroendocrinol 24 2012 1106 1119
70. S.Y. Romero-Zerbo, A. Rafacho, A. Diaz-Arteaga, J. Suarez, I. Quesada, and M. Imbernon et al. A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans J Endocrinol 211 2011 177 185
71. E.D. Rosen, and B.M. Spiegelman Molecular regulation of adipogenesis Annu Rev Cell Dev Biol 16 2000 145 171
72. S.A. Rosenzweig, and H.S. Atreya Defining the pathway to insulin-like growth factor system targeting in cancer Biochem Pharmacol 80 2010 1115 1124
73. E. Rozengurt, J. Sinnett-Smith, and K. Kisfalvi Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer Clin Cancer Res 16 2010 2505 2511
74. K.K. Ryan, B. Li, B.E. Grayson, E.K. Matter, S.C. Woods, and R.J. Seeley A role for central nervous system PPAR-gamma in the regulation of energy balance Nat Med 17 2011 623 626
75. V.T. Samuel, K.F. Petersen, and G.I. Shulman Lipid-induced insulin resistance: unravelling the mechanism Lancet 375 2010 2267 2277
76. E. Santini, P. Fallahi, S.M. Ferrari, A. Masoni, A. Antonelli, and E. Ferrannini Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells Diabetes 53 Suppl. 3 2004 S79 S83
77. U. Seedorf, and J. Aberle Emerging roles of PPARdelta in metabolism Biochim Biophys Acta 1771 2007 1125 1131
78. C. Sell, M. Rubini, R. Rubin, J.P. Liu, A. Efstratiadis, and R. Baserga Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor Proc Natl Acad Sci U S A 90 1993 11217 11221
79. R.K. Semple, V.K. Chatterjee, and S. O'Rahilly PPAR gamma and human metabolic disease J Clin Invest 116 2006 581 589
80. K. Shimomura, H. Shimizu, M. Ikeda, S. Okada, M. Kakei, and S. Matsumoto et al. Fenofibrate, troglitazone, and 15-deoxy-delta12,14-prostaglandin J2 close KATP channels and induce insulin secretion J Pharmacol Exp Ther 310 2004 1273 1280
81. J. Sinnett-Smith, K. Kisfalvi, R. Kui, and E. Rozengurt Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK Biochem Biophys Res Commun 430 2013 352 357
82. J.C. Sipe, T.M. Scott, S. Murray, O. Harismendy, G.M. Simon, and B.F. Cravatt et al. Biomarkers of endocannabinoid system activation in severe obesity PLoS One 5 2010 e8792
83. U. Smith, and E.A. Gale Cancer and diabetes: are we ready for prime time? Diabetologia 53 2010 1541 1544
84. S. Song, B. Liu, D. Baker, G.C. Huang, S.A. Amiel, and A.J. King et al. Islet GPR55 is coupled to increased insulin secretion and decreased apoptosis Diabetologia 55 Suppl. 1 2012 378 (Abstract)
85. C.E. Spivak, W. Kim, Q.R. Liu, C.R. Lupica, and M.E. Doyle Blockade of beta-cell K(ATP) channels by the endocannabinoid, 2-arachidonoylglycerol Biochem Biophys Res Commun 423 2012 13 18
86. L.S. Steelman, W.H. Chappell, S.L. Abrams, R.C. Kempf, J. Long, and P. Laidler et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging Aging (Albany NY) 3 2011 192 222
87. S. Steffens, N.R. Veillard, C. Arnaud, G. Pelli, F. Burger, and C. Staub et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice Nature 434 2005 782 786
88. R.J. Stevens, R. Ali, C.R. Bankhead, M.A. Bethel, B.J. Cairns, and R.P. Camisasca et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials Diabetologia 55 2012 2593 2603
89. L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, and S. Rossner Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397
90. P. Vigneri, F. Frasca, L. Sciacca, G. Pandini, and R. Vigneri Diabetes and cancer Endocr Relat Cancer 16 2009 1103 1123
91. A. Vilches-Flores, A.C. Hauge-Evans, P.M. Jones, and S.J. Persaud Chronic activation of cannabinoid receptors in vitro does not compromise mouse islet function Clin Sci (Lond) 124 2013 467 478
92. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli Cellular and molecular mechanisms of metformin: an overview Clin Sci (Lond) 122 2012 253 270
93. W.T. Wong, X.Y. Tian, A. Xu, J. Yu, C.W. Lau, and R.L. Hoo et al. Adiponectin is required for PPARgamma-mediated improvement of endothelial function in diabetic mice Cell Metab 14 2011 104 115
94. K. Zaugg, Y. Yao, P.T. Reilly, K. Kannan, R. Kiarash, and J. Mason et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress Genes Dev 25 2011 1041 1051
95. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, and J. Fenyk-Melody et al. Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 2001 1167 1174
96. X.H. Zhou, Q. Qiao, B. Zethelius, K. Pyorala, S. Soderberg, and A. Pajak et al. Diabetes, prediabetes and cancer mortality Diabetologia 53 2010 1867 1876